Home » Business News » 2012 » October » October 22, 2012


October 22, 2012 - LUND, SWEDEN

Newly Presented Data at 20(th) United European Gastroenterology (UEG)Week Conference Show Significant Impact of Laquinimod on Clinical Remissionversus Placebo

Jerusalem, Israel and Lund, Sweden, October 22, 2012 - TevaPharmaceuticalIndustries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI)today announced the presentation of Phase IIa clinical data forinvestigationallaquinimod in moderate to severe Crohn's disease (CD). The findingsdemonstratedthat treatment with orally administered laquinimod 0.5 mg/day resultedin arobust, early and consistent effect on remission (48.3% vs. 15.9% ofpatients,respectively) and response rates (62.1% vs. 34.9% of patients,respectively) inpatients with moderate-to-severe CD versus placebo. The data were reportedin anoral presentation at the 20(th) United European Gastroenterology (UEG)Weekconference

The full abstract can be found at:

"Our developmental program for laquinimod has demonstrated thattheimmunomodulatory effects of this oral compound stand to apply tomultipleautoimmune diseases, and data presented at UEG showed an impressiveimpact onclinical remission in Crohn's disease as early as one week of treatment,"saidDr. Michael Hayden, President of Global R&D and Chief ScientificOfficer forTeva Pharmaceutical Industries, Ltd. "These data provide a solidrationale forpotential future study of laquinimod in Crohn's disease."

The Phase IIa study evaluated the safety and efficacy of variousdoses oflaquinimod (0.5, 1, 1.5, or 2 mg/day) compared to placebo in active CDovereight weeks of treatment with four weeks of follow up. No effect wasnoted onremission/response at higher doses. Additionally, laquinimod 0.5 mg and1 mgdoses were generally well-tolerated, with adverse events similar to thoseseenwith placebo. The data are currently undergoing further analysis andevaluationto finalize next steps in the CD clinical development plan.


The Phase IIa, multicenter, randomized, double-blind, placebo-controlledtrialwas designed to evaluate the safety and efficacy of laquinimod in 180patientswith moderate to severe active CD, based on a CD Activity Index(CDAI) of220-450 and serum C-reactive protein (CRP) levels of >5mg/L ormucosalulcerations evident on a recent endoscopy. The study tracked four dosecohortswho received laquinimod 0.5 mg/day, 1 mg/day, 1.5 mg/day, 2 mg/day, orplacebofor eight weeks with four weeks follow-up. Approximately 45 patientswereenrolled in each cohort in a 2:1 ration between laquinimod andplacebo.Stableconcomitant therapies and prior anti-tumor necrosis factor (TNF) useamongpatients was permitted in the study.


Laquinimod is a novel oral immunomodulator under clinical developmentfor thetreatment of multiple sclerosis (MS), Crohn's disease (CD) and systemiclupuserythematosus (SLE or lupus). Human and animal models suggest laquinimodexertsits therapeutic effect by modulating the immune system cells, mainlyresultingin a down regulation of pro-inflammatory cytokines.

ABOUT Crohn's disease

CD is a chronic inflammatory condition that affects the gastrointestinaltract.The symptoms of CD can vary significantly among afflicted individuals. Themaingastrointestinal symptoms are abdominal pain, diarrhea, or weight loss.CD canalso cause complications outside of the gastrointestinal tract such asskinrashes, arthritis, and inflammation of the eye.The precise cause of CD is not known. CD is considered to be anautoimmunedisease. This autoimmune activity produces inflammation in thegastrointestinaltract. CD is classified as an inflammatory bowel disease, IBD.


Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading globalpharmaceutical company, committed to increasing access to high-qualityhealthcare by developing, producing and marketing affordable generic drugsaswell as innovative and specialty pharmaceuticals and active pharmaceuticalingredients. Headquartered in Israel, Teva is the world's largest genericdrugmaker, with a global product portfolio of more than 1,300 molecules and adirectpresence in about 60 countries. Teva's branded businesses focus on CNS,oncology, pain, respiratory and women's health therapeutic areas as well asbiologics. Teva currently employs approximately 46,000 people around theworldand reached $18.3 billion in net revenues in 2011.


Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company withfocus on autoimmune/inflammatory diseases and cancer. Projects in orenteringpivotal phase are laquinimod, an orally administered small molecule withuniqueimmunomodulatory properties for the treatment of multiple sclerosis, TASQforprostate cancer as well as ANYARA for use in cancer targeted therapy,primarilyof renal cell cancer. In addition, laquinimod is in Phase II developmentforCrohn's and Lupus. Further projects in clinical development comprise thetwoorally administered compounds, 57-57 for SLE & Systemic Sclerosis andRhuDex™for RA. Please visit for more information.

Teva's Safe Harbor Statement under the U. S. Private Securities LitigationReform Act of 1995:

This release contains forward-looking statements, which express the currentbeliefs and expectations of management. Such statements are based onmanagement's current beliefs and expectations and involve a number of knownandunknown risks and uncertainties that could cause our future results,performanceor achievements to differ significantly from the results, performance orachievements expressed or implied by such forward-looking statements.Importantfactors that could cause or contribute to such differences include risksrelating to: our ability to successfully develop and commercializeadditionalpharmaceutical products, the introduction of competing generic equivalents,theextent to which we may obtain U.S. market exclusivity for certain of ournewgeneric products and regulatory changes that may prevent us from utilizingexclusivity periods, potential liability for sales of generic productsprior toa final resolution of outstanding patent litigation, including thatrelating tothe generic version of Protonix®, the extent to which any manufacturingorquality control problems damage our reputation for high quality production,theeffects of competition on sales of our innovative products, especiallyCopaxone® (including potential generic and oral competition forCopaxone®),the impact of continuing consolidation of our distributors and customers,ourability to identify, consummate and successfully integrate acquisitions(including the acquisition of Cephalon), interruptions in our supply chainorproblems with our information technology systems that adversely affect ourcomplex manufacturing processes, intense competition in our specialtypharmaceutical businesses, any failures to comply with the complex MedicareandMedicaid reporting and payment obligations, our exposure to currencyfluctuations and restrictions as well as credit risks, the effects ofreforms inhealthcare regulation, adverse effects of political or economicalinstability,major hostilities or acts of terrorism on our significant worldwideoperations,increased government scrutiny in both the U.S. and Europe of our agreementswithbrand companies, dependence on the effectiveness of our patents and otherprotections for innovative products, our ability to achieve expectedresultsthrough our innovative R&D efforts, the difficulty of predicting U.S. FoodandDrug Administration, European Medicines Agency and other regulatoryauthorityapprovals, uncertainties surrounding the legislative and regulatory pathwayforthe registration and approval of biotechnology-based products, potentiallysignificant impairments of intangible assets and goodwill, potentialincreasesin tax liabilities resulting from challenges to our intercompanyarrangements,our potential exposure to product liability claims to the extent notcovered byinsurance, the termination or expiration of governmental programs or taxbenefits, current economic conditions, any failure to retain key personnelor toattract additional executive and managerial talent, environmental risks andother factors that are discussed in our Annual Report on Form 20-F andotherfilings with the U.S. Securities and Exchange Commission.

Active Biotech's Safe Harbor Statement in Accordance with the SwedishSecuritiesMarket Act:

This press release contains certain forward-looking statements. Suchforward-looking statements involve known and unknown risks, uncertainties and otherimportant factors that could cause the actual results, performance orachievements of the company, or industry results, to differ materially fromanyfuture results, performance or achievement implied by the forward-lookingstatements. The company does not undertake any obligation to update orpubliclyrelease any revisions to forward-looking statements to reflect events,circumstances or changes in expectations after the date of this pressrelease.

Active Biotech is obligated to publish the information contained in thispressrelease in accordance with the Swedish Securities Market Act. Thisinformationwas provided to the media for publication 3:00 p.m. CET on October 22,2012.


This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE[HUG#1651043]

IR Contacts:
Kevin C. Mannix
United States
(215) 591-8912

Joseph Marczely
United States
(267) 468-4281

Tomer Amitai
972 (3) 926-7656

PR Contacts
Hadar Vismunski-Weinberg
972 (3) 926-7687

Denise Bradley
United States
(215) 591-8974

Active Biotech
Tomas Leanderson
Active Biotech AB

Hans Kolam
Active Biotech AB


Comment on this story